Osaka NeuroTherapeutics
Headquarters: Osaka, Japan
Founded: 2023 (Osaka University spin-out)
Focus: BDNF mimetics for Alzheimer's disease
Website: https://www.osakaneuro.jp
Overview
flowchart TD
institutions_osaka_neurotherap["Osaka NeuroTherapeutics"]
style institutions_osaka_neurotherap fill:#4fc3f7,stroke:#333,color:#000
institutions_osaka_n_0["Scientific Foundation"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_0
style institutions_osaka_n_0 fill:#81c784,stroke:#333,color:#000
institutions_osaka_n_1["BDNF/TrkB Signaling Pathway"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_1
style institutions_osaka_n_1 fill:#ef5350,stroke:#333,color:#000
institutions_osaka_n_2["BDNF Deficiency in Alzheimers Disease"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_2
style institutions_osaka_n_2 fill:#ffd54f,stroke:#333,color:#000
institutions_osaka_n_3["Therapeutic Strategies for BDNF Restoration"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_3
style institutions_osaka_n_3 fill:#ce93d8,stroke:#333,color:#000
institutions_osaka_n_4["Pipeline"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_4
style institutions_osaka_n_4 fill:#4fc3f7,stroke:#333,color:#000
institutions_osaka_n_5["ONT-301 Lead Program"]
institutions_osaka_neurotherap -->|"includes"| institutions_osaka_n_5
style institutions_osaka_n_5 fill:#81c784,stroke:#333,color:#000
...Osaka NeuroTherapeutics
Headquarters: Osaka, Japan
Founded: 2023 (Osaka University spin-out)
Focus: BDNF mimetics for Alzheimer's disease
Website: https://www.osakaneuro.jp
Overview
Mermaid diagram (expand to render)
Osaka NeuroTherapeutics (ONT) is an Osaka University spin-out company developing brain-derived neurotrophic factor (BDNF) mimetic compounds for the treatment of Alzheimer's disease and related dementias. The company's approach addresses the well-documented decline in BDNF signaling that occurs early in Alzheimer's disease pathogenesis, proposing that restoring BDNF/TrkB signaling can protect vulnerable neurons and support cognitive function["@ont2024"].
BDNF is the most abundant neurotrophin in the central nervous system and is critical for neuronal survival, synaptic plasticity, and memory formation. Multiple studies have demonstrated reduced BDNF expression in the hippocampus and cortex of Alzheimer's disease patients, and experimental models show that BDNF deficiency accelerates amyloid pathology and cognitive decline["@bdnf_deficiency_ad"]. Osaka NeuroTherapeutics was founded to translate these findings into disease-modifying therapies.
Scientific Foundation
BDNF/TrkB Signaling Pathway
BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, a tyrosine kinase that is the primary mediator of BDNF's neurotrophic effects[@bdnf_trkb_signaling]. Upon ligand binding, TrkB dimerizes and autophosphorylates, activating downstream signaling cascades:
- PLC-gamma pathway: Generates DAG and IP3, leading to PKC activation and calcium release
- PI3K/Akt pathway: Promotes neuronal survival and protein synthesis
- Ras/ERK pathway: Regulates gene expression, synaptic plasticity, and memory consolidation
These pathways converge to promote synaptic spine formation, enhance long-term potentiation (LTP), support dendritic arborization, and protect neurons against excitotoxic and oxidative stress[@bdnf_trkb_signaling].
BDNF Deficiency in Alzheimer's Disease
Multiple mechanisms contribute to reduced BDNF signaling in Alzheimer's disease:
Transcriptional downregulation: Amyloid-beta and inflammatory cytokines suppress BDNF gene expression
Receptor dysfunction: TrkB signaling becomes impaired through various mechanisms
Reduced synaptic activity: Less neuronal activity means less activity-dependent BDNF release
Age-related decline: BDNF expression naturally decreases with age, compounding disease effects[@bdnf_deficiency_ad]Therapeutic Strategies for BDNF Restoration
Osaka NeuroTherapeutics is pursuing multiple approaches to restore BDNF/TrkB signaling:
Small Molecule TrkB Agonists
Non-peptidic TrkB agonists that bind and activate the receptor represent an attractive therapeutic approach. Unlike BDNF itself (which cannot cross the BBB), small molecule agonists can be administered orally and achieve adequate CNS exposure[@trkb_agonists].
BDNF Mimetic Peptides
Peptide fragments of BDNF that retain receptor-binding and activation activity offer a middle ground between full proteins and small molecules. These peptides can be optimized for stability and brain penetration while maintaining the key functional domains[@bdnf_mimetic_peptide].
Gene Therapy Approaches
Viral vector delivery of BDNF to specific brain regions (particularly the hippocampus and basal forebrain) provides sustained local expression of the neurotrophin.
Pipeline
ONT-301 (Lead Program)
Target: TrkB agonist
Stage: Lead optimization
Indication: Alzheimer's disease (mild cognitive impairment to mild dementia)
ONT-301 is a small molecule TrkB agonist with optimized pharmacokinetics for CNS penetration. Preclinical data demonstrate:
- Activation of TrkB signaling in primary neurons (phosphorylation at Y816)
- Improvement in synaptic function in APP/PS1 mice (enhanced LTP)
- Cognitive improvement in multiple behavioral paradigms (Morris water maze, novel object recognition)
- Oral bioavailability and good brain penetration in rodents and non-human primates
ONT-302 (Secondary Program)
Target: BDNF mimetic peptide
Stage: Hit-to-lead
Indication: Alzheimer's disease, vascular dementia
ONT-302 is a cyclic peptide that mimics the receptor-binding interface of BDNF. The peptide is being optimized for stability and brain penetration through various peptide delivery strategies.
Connection to NeuroWiki Topics
Osaka NeuroTherapeutics' work intersects with key mechanisms in NeuroWiki:
- [BDNF signaling in neurodegeneration](/mechanisms/bdnf-neurodegeneration)
- [Neurotrophic factor therapeutics landscape](/investment/neurotrophic-factors)
- [Synaptic transmission and plasticity mechanisms](/mechanisms/synaptic-transmission)
- [Cognitive enhancers therapeutic landscape](/therapeutics/cognitive-enhancers)
- [Hippocampal CA1 pyramidal neurons and memory](/cell-types/hippocampal-ca1-memory)
Pathway Diagram
The following diagram shows the key molecular relationships involving Osaka NeuroTherapeutics discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)